Fennec Pharmaceuticals Inc.
Price
Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Fennec Pharmaceuticals Inc., its business model, key products, and controversies.